Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CureVac NV

CVAC
Current price
2.67 USD -0.08 USD (-2.91%)
Last closed 2.75 USD
ISIN NL0015436031
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 637 051 712 USD
Yield for 12 month -51.72 %
1Y
3Y
5Y
10Y
15Y
CVAC
21.11.2021 - 28.11.2021

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.92 USD

P/E ratio

Dividend Yield

Current Year

+56 120 681 USD

Last Year

+71 856 032 USD

Current Quarter

+15 463 664 USD

Last Quarter

+13 187 106 USD

Current Year

-97 072 766 USD

Last Year

-124 243 151 USD

Current Quarter

-33 278 587 USD

Last Quarter

-31 244 904 USD

Key Figures CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -270 342 016 USD
Operating Margin TTM -493.58 %
PE Ratio
Return On Assets TTM -24.52 %
PEG Ratio
Return On Equity TTM -54.3 %
Wall Street Target Price 7.92 USD
Revenue TTM 65 859 000 USD
Book Value 1.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 90.5 %
Dividend Yield
Gross Profit TTM -91 549 000 USD
Earnings per share -1.34 USD
Diluted Eps TTM -1.34 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CVAC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 5.2356
Enterprise Value Revenue 6.3905
Price Sales TTM 9.673
Enterprise Value EBITDA -0.6624
Price Book MRQ 1.571

Financials CVAC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CVAC

For 52 weeks

2.22 USD 6.3 USD
50 Day MA 2.95 USD
Shares Short Prior Month 4 785 625
200 Day MA 3.24 USD
Short Ratio 11.67
Shares Short 4 708 812
Short Percent 11.75 %